EGFR and non-small cell lung carcinoma: On the other hand, however, a study by Kurppa et al. [210] suggests that YAP activity is essential for conferring resistance to combined EGFR-MEK inhibition, thereby inducing dormancy in an EGFR-mutated non-small cell lung cancer model.